| Similar Articles |
|---|
 |
The Motley Fool
April 7, 2011
Brandon Glenn |
"Generic Wave" to Drive Cardinal Health's Profitability in Coming Years The generic wave could mean big money for Cardinal and top competitors.   |
The Motley Fool
May 20, 2004
Tom Taulli |
Cardinal Rules of M&A Cardinal Health is upbeat on its latest acquisition, but needs bigger deals to push growth. |
The Motley Fool
June 13, 2006
Ryan Fuhrmann |
Cardinal Looks to Deliver Cardinal Health has been through a tumultuous couple of years but appears to have weathered company-specific and industry storms. If the drug distributor can meet its long-term goals, then its stock should represent a long-term solid investment. |
The Motley Fool
December 10, 2004
Brian Gorman |
Cardinal Picks a Lilly Cardinal Health's deal with Lilly suggests the new fee-for-service model is gaining traction. |
The Motley Fool
October 28, 2004
Brian Gorman |
Cardinal's Good News: No News The drug wholesaler took a major step toward rehabilitating itself with the release of its 10-K. |
The Motley Fool
August 3, 2006
Ryan Fuhrmann |
Cardinal Distributes the Goods The drug wholesaler and distributor has to regain investor confidence and rebuild a track record in a changed industry. So far, so good for 2006. Let's see if any further information can be found once Cardinal submits its 10-K filing to the SEC. |
The Motley Fool
July 1, 2004
W.D. Crotty |
Drug Wholesalers Taking a Beating A sharp drop at drug wholesaler Cardinal Health provides a unique buying opportunity. |
The Motley Fool
January 26, 2007
Billy Fisher |
A Clean Bill of Health at Cardinal Good results and a key divestiture have this health care company rolling. Investors, take note. |
The Motley Fool
January 30, 2006
Brian Gorman |
Cardinal Inches Higher The distribution is looking healthier, but Cardinal Health still has work to do. Investors, take note. |
The Motley Fool
August 24, 2011
Brandon Glenn |
Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge? |
The Motley Fool
June 28, 2005
Brian Gorman |
Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news. |
BusinessWeek
August 30, 2004
Gene G. Marcial |
PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell. |
The Motley Fool
September 30, 2008
Brian Orelli |
Cardinal Health Clips Its Wings Does it make sense for the drug wholesaler to spin off its medical equipment business? |
The Motley Fool
November 8, 2011
Brandon Glenn |
Cardinal Health Looks to Build China Business, but Has Long Way to Go For pharmaceuticals distributor Cardinal Health, China represents a world of opportunity. |
The Motley Fool
September 2, 2009
Brian Orelli |
Should You Buy This Spinoff? Cardinal Health kicks its baby out of the nest. |
Chemistry World
March 3, 2015
Phillip Broadwith |
J&J to sell cardiac devices to wholesaler Cardinal Johnson & Johnson has agreed to sell its cardiovascular surgical devices subsidiary, Cordis, to wholesale supplier Cardinal Health. |
The Motley Fool
January 21, 2005
Rich Duprey |
Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all. |
CFO
March 1, 2004
Joseph McCafferty |
Going for Growth Finding new sources of revenue is harder than ever. Here's how to grow without damaging your roots. |
The Motley Fool
November 7, 2007
Billy Fisher |
Cardinal Has Its Wings Clipped Despite a healthy year-over-year pop of 15% in EPS from operations, much of the focus in the first-quarter was shifted to a weak performance by Cardinal's pharmaceutical services segment. |
The Motley Fool
August 1, 2006
Selena Maranjian |
Prescription for Prescription Bargains Did you know that your medications might be cheaper around the corner? Another way to offset your net expenses on medications is to make some money on drugs -- by investing in drug-related firms. |
The Motley Fool
October 26, 2005
Stephen D. Simpson |
Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it. |
Pharmaceutical Executive
February 1, 2011
Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country |
The Motley Fool
September 9, 2011
Brandon Glenn |
Cardinal Health Looks to PET Drugs to Drive Margins The nuclear medicine business is an important driver of higher margins for the drug distribution company. |
The Motley Fool
January 2, 2004
Alyce Lomax |
A Bitter Pill for Amerisource Veterans ditch Amerisource for rival; investors punish the entire pharmaceutical distribution industry. |
The Motley Fool
July 28, 2004
Brian Gorman |
Cardinal Watching Cardinal Health continues to be pummeled, but wait patiently, because a buying opportunity could emerge. |
The Motley Fool
October 6, 2008
Brian Orelli |
Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated. |
The Motley Fool
May 2, 2008
Steven Renaldi |
Cardinal Health Gets Its Nest in Order Share price rises as investors hope the company is beginning to put some of its troubles behind it. |
The Motley Fool
June 27, 2011
Brandon Glenn |
Cardinal Health Products Won't Be in Cleveland Medical Mart (or Any Other) Once an early high-profile supporter of the medical mart concept, drug distributor Cardinal Health has had an apparent change of opinion. |
The Motley Fool
May 2, 2005
Brian Gorman |
Cardinal Health Perks Up The drug distribution company is working through its problems, which should make for a brighter fiscal 2006. Investors, take note. |
The Motley Fool
August 5, 2005
Stephen D. Simpson |
Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future. |
The Motley Fool
May 7, 2010
Brian Orelli |
Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies. |
The Motley Fool
May 6, 2008
Steven Renaldi |
McKesson Garners Generic Growth New products offer the generic-drug distributor profit potential in a competitive industry. |
The Motley Fool
May 6, 2005
W.D. Crotty |
McKesson's New Pep Pill The drug wholesaler reports strong fourth-quarter results as it moves to a fee-for-service model. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
October 8, 2007
Billy Fisher |
McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note. |
The Motley Fool
March 23, 2011
Jordan DiPietro |
Should You Buy and Hold Cardinal Health? Does this company have the traits of a good retirement stock? |
The Motley Fool
September 9, 2009
Brian Orelli |
Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right. |
Fast Company
April 2004
Alison Overholt |
Smart Strategies: Putting Ideas To Work "There have been several great eras in strategy," says one consultant. "This is not one of them." Still, there are signs of a renewed appetite for new thoughts. To get a sense of the enduring power of a big idea, we look at five companies that are putting smart strategies into action. |
